Intratumoral Heterogeneity of Immunohistochemical Marker Expression in Breast Carcinoma: A Tissue Microarray-based Study

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Applied immunohistochemistry & molecular morphology (Print)

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/PAI.0b013e3181dddb20PMID 20485156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

  2009cited by this paper
• Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype

  2007cited by this paper
• Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

  2007cited by this paper
• Intratumoral Heterogeneity of HER2/neu in Breast Cancer—A Rare Event

  2007cited by this paper
• Intratumor heterogeneity of biomarker expression in breast carcinomas

  2004influential reference
• Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics.

  2004cited by this paper
• HER-2/neu (c-erbB-2) Evaluation in Primary Breast Carcinoma by Fluorescent In Situ Hybridization and Immunohistochemistry With Special Focus on Intratumor Heterogeneity and Comparison of Invasive and In Situ Components

  2004cited by this paper
• Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls

  2004cited by this paper
• Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer

  2002cited by this paper
• Breast cancer genetics: what we know and what we need

  2001cited by this paper
• Breast cancer genetics: What we know and what we need

  2001cited by this paper
• Molecular targets for breast cancer therapy and prevention

  2001cited by this paper
• Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.

  2000cited by this paper
• Marked Intratumoral Heterogeneity of the Proto‐Oncogene Her‐2/neu Determined by Three Different Detection Systems

  1999cited by this paper
• Heterogeneity of DNA Distribution in Diploid Cells: A New Predicitive Discriminant Factor for Solid Tumour Behaviour

  1999cited by this paper
• Sequential assessment of multidrug resistance phenotype and measurement of S‐phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy

  1996cited by this paper
• Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry.

  1996cited by this paper
• Geographic distribution of co-dominant DNA stemlines in breast carcinoma.

  1995cited by this paper
• Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions.

  1995cited by this paper
• Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects.

  1995cited by this paper
• Expression of bcl-2 gene confers multidrug resistance to chemotherapy- induced cell death

  1994cited by this paper
• Biological heterogeneity of er‐positive breast cancers in the post‐menopausal population

  1994cited by this paper
• Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis.

  1993cited by this paper
• Proliferation index as a prognostic marker in breast cancer

  1993cited by this paper
• One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?

  1992cited by this paper
• Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer.

  1991cited by this paper
• Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptors, dna ploidy

  1991cited by this paper
• Ploidy Analysis and S‐Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomas of the Breast

  1991cited by this paper
• Immunohistologic heterogeneity of malignant tumors.

  1988cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Dissociation between the expression of cGAS/STING and a senescence-associated signature in colon cancer

  2025cites this paper
• DEPTH2 score was associated with cell proliferation and immune cell infiltrations but not with systemic treatment response in breast cancer

  2025cites this paper
• A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer

  2024cites this paper
• DEPTH2 score was associated with cell proliferation and immune cell infiltrations but not with systemic treatment response in breast cancer

  2024cites this paper
• Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression

  2023cites this paper
• Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay

  2023cites this paper
• Ultrasound-based radiomics model for predicting molecular biomarkers in breast cancer

  2023cites this paper
• The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness

  2023cites this paper
• FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma

  2023cites this paper
• Metabolic Heterogeneity of Tumors

  2023cites this paper
• Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Based on Intratumoral and Peritumoral DCE-MRI Radiomics Nomogram

  2022cites this paper
• Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.

  2022cites this paper
• A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone

  2022cites this paper
• Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review

  2022cites this paper
• HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features

  2021cites this paper
• Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets

  2021cites this paper
• ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

  2021cites this paper
• ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

  2021cites this paper
• Spatially resolved determination of the abundance of the HER2 marker in microscopic breast tumors using targeted SERS imaging

  2021cites this paper
• Case Report: Rare Case of Synchronous Neck Metastasis From Metachronous Bilateral Renal Cell Carcinoma

  2021cites this paper
• Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing

  2021cites this paper
• Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma

  2021cites this paper
• Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma

  2021cites this paper
• PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Intratumoral heterogeneity of glutaminase and lactate dehydrogenase A protein expression in colorectal cancer

  2020cites this paper
• Breast Cancer Heterogeneity and Response to Novel Therapeutics

  2020cites this paper
• Marked epithelial to mesenchymal transition in surgical margins of oral cancer-an in vitro study

  2020cites this paper
• Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment

  2020cites this paper
• Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction

  2020cites this paper
• A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

  2019cites this paper
• PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance

  2019cites this paper
• Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations.

  2019cites this paper
• Precision Oncology : Bridging the Knowledge Gap with Multi-Omics

  2018cites this paper
• High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.

  2018cites this paper
• Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer

  2018cites this paper
• Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions

  2018cites this paper
• Impact of intratumoral heterogeneity of breast cancer tissue on quantitative metabolomics using high‐resolution magic angle spinning 1H NMR spectroscopy

  2018cites this paper
• Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer

  2018cites this paper
• Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.

  2018cites this paper
• Correction to: Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer

  2018cites this paper
• Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival

  2018cites this paper
• Unmasking tumor heterogeneity and clonal evolution by single-cell analysis

  2018cites this paper
• Viewing the Eph receptors with a focus on breast cancer heterogeneity.

  2018cites this paper
• Predictive value for lymph node metastasis of epithelial-mesenchymal transition and cancer stem cell marker expression in early gastric cancer.

  2017cites this paper
• Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images

  2017cites this paper
• Tumor Heterogeneity in Breast Cancer

  2017cites this paper
• Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures

  2017cites this paper
• Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

  2017cites this paper
• Intratumor and Intertumor Heterogeneity in Melanoma

  2017cites this paper
• Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

  2017cites this paper
• Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors

  2017cites this paper
• In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer.

  2017cites this paper
• Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume

  2017cites this paper
• Cooperating Oncogenic Alterations in Aggressive Pten-Deficient Breast Cancer

  2017cites this paper
• Molecular heterogeneity in breast cancer: State of the science and implications for patient care.

  2017cites this paper
• Neural Analyses Validate and Emphasise the Role of Progesterone Receptor in Breast Cancer Progression and Prognosis

  2016cites this paper
• Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours

  2016influential citation
• Neural Analyses Validate and Emphasize the Role of Progesterone Receptor in Breast Cancer Progression and Prognosis.

  2016cites this paper
• Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist

  2016cites this paper
• Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics

  2016cites this paper
• Snail heterogeneity in clear cell renal cell carcinoma

  2016cites this paper
• Intratumoral Agreement of High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopic Profiles in the Metabolic Characterization of Breast Cancer

  2016cites this paper
• Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

  2016cites this paper
• A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data

  2015cites this paper
• Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis

  2015cites this paper
• Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma

  2015cites this paper
• Prediction of Response to Aromatase Inhibitors in Breast Cancer

  2015cites this paper
• Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

  2015cites this paper
• HER2 assessment by silver in situ hybridization: where are we now?

  2015cites this paper
• Evaluation of Ki67 Expression across Distinct Categories of Breast Cancer Specimens: A Population-Based Study of Matched Surgical Specimens, Core Needle Biopsies and Tissue Microarrays

  2014cites this paper
• Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial Cancer1

  2014cites this paper
• Transcription factors related to epithelial mesenchymal transition in tumor center and margin in invasive lung adenocarcinoma.

  2014cites this paper
• Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair‐matched immunohistochemical analysis aimed at intrinsic tumor phenotype

  2014cites this paper
• Tissue microarrays in non-small-cell lung cancer: reliability of immunohistochemically-determined biomarkers.

  2014cites this paper
• Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous

  2014cites this paper
• KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma

  2014cites this paper
• A novel, automated technology for multiplex biomarker imaging and application to breast cancer

  2014cites this paper
• STAG2 expression in oral cancer and potentially malignant lesions

  2014cites this paper
• Implications of intratumour heterogeneity for treatment stratification

  2014cites this paper
• Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes

  2014cites this paper
• Ki-67 antigeenin värjäytyvyys rinnan leikkauspreparaatissa verrattuna saman potilaan paksuneulabiopsiaan

  2014cites this paper
• Authors' reply: combining two antibodies to define E‐cadherin loss of expression in non‐lobular breast carcinomas: when less is more

  2013cites this paper
• Discrepancies Between HER 2 Assessment from Core Needle Biopsies and Surgical Specimens of Invasive Ductal Breast Carcinoma

  2013cites this paper
• Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.

  2013cites this paper
• Characterising response and resistance mechanisms toFaslodex in breast cancer

  2013cites this paper
• Intratumor heterogeneity: Nature and biological significance

  2013cites this paper
• Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

  2013cites this paper
• Discrepancies between HER2 assessment from core needle biopsies and surgical specimens of invasive ductal breast carcinoma.

  2013cites this paper
• EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

  2012cites this paper
• ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

  2012cites this paper
• Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers.

  2012cites this paper
• Development of Multigene Expression Signature Maps at the Protein Level from Digitized Immunohistochemistry Slides

  2012cites this paper
• Intratumoral heterogeneity of microRNA expression in breast cancer.

  2012cites this paper
• Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

  2012cites this paper
• Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

  2012cites this paper
• Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes

  2012cites this paper
• Common Protein Biomarkers Assessed by Reverse Phase Protein Arrays Show Considerable Intratumoral Heterogeneity in Breast Cancer Tissues

  2012cites this paper
• Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma.

  2012cites this paper
• Concordance Between Tissue Microarray and Whole-section Estrogen Receptor Expression and Intratumoral Heterogeneity

  2012influential citation
• Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry.

  2012cites this paper